Clinical Study
Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
Table 1
Baseline characteristics.
| | Patients () |
| Median age (range) | 70 (51–87) |
| Race | Caucasian 9 (60%) African American 6 (40%) |
| Performance status | Zero 9 (60%) One 6 (40%) |
| Prior local treatment | Prostatectomy 3 (20%); radiation 14 (93%); cryotherapy 1 (7%) |
| Other prior therapies | Antiandrogen 13 (86%) Ketoconazole 3 (20%) Steroid 2 (13%) |
| Gleason score | Six 4 (27%); seven 4 (27%), eight 1 (7%), nine 6 (40%) |
| Median pretreatment PSA [ng/mL] (range) | 27 (2.6–104) | Median Hgb [g/dL] (range) | 12.9 (9.9–15.5) |
|
|